Publication:
Bacterial DNA translocation and liver disease severity among HIV-infected patients with chronic hepatitis C

dc.contributor.authorGarcia-Alvarez, Monica
dc.contributor.authorBerenguer, Juan
dc.contributor.authorGuzman-Fulgencio, Maria
dc.contributor.authorAlvarez, Emilio
dc.contributor.authorCosín, Jaime
dc.contributor.authorMicheloud, Dariela
dc.contributor.authorJimenez-Sousa, Maria Angeles
dc.contributor.authorFernandez-Rodriguez, Amanda
dc.contributor.authorAldámiz-Echevarria, Teresa
dc.contributor.authorCarrero, Ana
dc.contributor.authorMiralles, Pilar
dc.contributor.authorResino, Salvador
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.contributor.funderRedes Temáticas de Investigación Cooperativa en Salud (RETICS) (España)es_ES
dc.contributor.funderFundación para la Investigación y la Prevención del Sida en Españaes_ES
dc.date.accessioned2024-02-03T21:28:47Z
dc.date.available2024-02-03T21:28:47Z
dc.date.issued2012-12-15
dc.description.abstractWe carried out a cross-sectional study to explore whether bacterial 16S ribosomal DNA (bactDNA) shows association with severity of liver disease among human immunodeficiency virus/hepatitis C virus coinfected patients. Patients with advanced fibrosis (F3/F4), moderate activity grade (A2/A3), and high fibrosis progression rate (FPR > 0.15) had higher values of plasma bactDNA levels than did patients without these markers of liver disease (P < 0.05). The chance of having a fibrosis stage or activity grade increased was 1.20 [95% confidence interval (CI) = 1.0 to 1.44, P = 0.045] and 1.22 (95% CI = 1.1 to 1.45, P = 0.029) times greater for every 100 copies per microliter of plasma bactDNA. Likewise, the odds of having values of FPR > 0.15 was 1.18 (95% CI = 0.98 to 1.42, P = 0.089). In addition, patients with high bactDNA levels (≥175 copies per microliter) had the highest odds of having high values of Metavir score and FPR (P < 0.05). Our data show that bacterial translocation is associated with severe liver disease among human immunodeficiency virus-infected patients with chronic hepatitis C.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipSupported by grants given by “Instituto de Salud Carlos III” (grant numbers PI08/0738, PI11/00245; ISCIII-RETIC RD06/006, and PI08/0928), and “Fundación para la Investigación y la Prevención del Sida en España” (grant numbers 36443/03 and 361020/10). A. Fernández-Rodríguez, M. Guzman-Fulgencio, M. García-Álvarez, and Mª A. Jimenez-sousa are supported by “Instituto de Salud Carlos III” (grant numbers UIPY1377/08, CM09/00031, CM08/00101, and CM10/00105, respectively).es_ES
dc.format.number5es_ES
dc.format.page552-556es_ES
dc.format.volume61es_ES
dc.identifier.citationJ Acquir Immune Defic Syndr. 2012 Dec 15;61(5):552-6.es_ES
dc.identifier.doi10.1097/QAI.0b013e31826ea109es_ES
dc.identifier.e-issn1944-7884es_ES
dc.identifier.journalJournal of acquired immune deficiency syndromes (1999)es_ES
dc.identifier.pubmedID22932319es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/17445
dc.language.isoenges_ES
dc.publisherLippincott Williams & Wilkins (LWW)es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MICINN//PI11%2F00245/ES/Erradicación del VHC en pacientes coinfectados por VIH%2FVHC: efectos sobre la inflamación, el daño endotelial, la activación inmune y la aterosclerosis preclínica/es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MICINN//CM09%2F00031/ES/CM09%2F00031/es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MICINN//CM08%2F00101/ES/CM08%2F00101/es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MICINN//CM10%2F00105/ES/CM10%2F00105/es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI08/0738es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/RD06/006es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI08/0928es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/UIPY1377/08es_ES
dc.relation.publisherversionhttps://doi.org/10.1097/QAI.0b013e31826ea109es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject16S rDNAes_ES
dc.subjectBacterial translocationes_ES
dc.subjectHepatitis Ces_ES
dc.subjectHIV/ AIDSes_ES
dc.subjectLiver biopsyes_ES
dc.subject.meshAdultes_ES
dc.subject.meshBase Sequencees_ES
dc.subject.meshBiological Transport, Activees_ES
dc.subject.meshCross-Sectional Studieses_ES
dc.subject.meshDNA, Bacteriales_ES
dc.subject.meshDisease Progressiones_ES
dc.subject.meshFemalees_ES
dc.subject.meshHIV Infectionses_ES
dc.subject.meshHepatitis C, Chronices_ES
dc.subject.meshHumanses_ES
dc.subject.meshIntestinal Mucosaes_ES
dc.subject.meshLiver Cirrhosises_ES
dc.subject.meshMalees_ES
dc.subject.meshRNA, Ribosomal, 16Ses_ES
dc.titleBacterial DNA translocation and liver disease severity among HIV-infected patients with chronic hepatitis Ces_ES
dc.typeresearch articlees_ES
dc.type.hasVersionAMes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication7b71e6d9-e421-4483-8961-fa252b845788
relation.isAuthorOfPublication946b9e38-f60e-4226-8735-78ceebc4111a
relation.isAuthorOfPublication2bf7faec-7f00-44ba-9494-efb396305551
relation.isAuthorOfPublication6a32a4a3-2d81-43c5-8295-48346efbf498
relation.isAuthorOfPublication89b17350-14e3-4dfd-b797-6ee6ca5363b8
relation.isAuthorOfPublication.latestForDiscovery7b71e6d9-e421-4483-8961-fa252b845788

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Bacterial_DNA_TranslocationLiverDisease_2012.pdf
Size:
1.42 MB
Format:
Adobe Portable Document Format
Description: